Efficacy and Safety of Tripterygium and its extracts Plus Irbesartan for Hypertensive Renal Damage

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039999

Enrollment

Unknown

Registered

2020-11-17

Start date

2020-11-18

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Renal Damage

Interventions

Group A:Irbesartan

Group B:tripterygium and its extracts plus irbesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Understand and have signed the informed consent; 2. Urine microalbumin >= 30mg/24h or Albumin/creatinine ratio>= 30mg/g (3.5mg/mmol); 3. eGFR30-60ml/min·1.73m2; 4. no cardiovascular and cerebrovascular events in four weeks; 5. negative pregnancy test and willing to contraception during treatment.

Exclusion criteria

Exclusion criteria: 1. Pregnancy, breastfeeding or malignant tumor; 2. eGFR < 30 ml /min·1. 73m2; 3. Patients with primary glomerulonephritis or with immune system diseases; 4. severe heart, liver or lung dysfunction; 5. no legal capacity or legal capacity is restricted; 6. disagree for the participation from researchers; 7. poor adherence.

Design outcomes

Primary

Measure	Time frame
24h urine protein quantification;Serum creatinine;Urea Nitrogen;eGFR;Plasma albumin;CRP;	—

Secondary

Measure	Time frame
Systolic pressure;Diastolic pressure;	—

Countries

China

Contacts

Public ContactHuang Hui

The Eighth Affiliated Hospital, Sun Yat-Sen University (Shenzhen Futian)

huanghui765@hotmail.com+86 13923730765

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026